The current study focuses on the development of pH-sensitive hydrogels for the controlled release of mesalamine at a specific pH. A free radical polymerization technique was used, and the formulated hydrogels were characterized by Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis, scanning electron microscopy, swelling and drug release studies. FTIR confirmed the successful formation of a polymeric network with efficient incorporation of the drug. TGA revealed that the hydrogel demonstrated significantly improved thermal stability compared to the unmodified polymer, with SEM images showing a rough surface with a notable porous structure. Swelling and drug release behaviors were assessed at 37 °C in buffer solutions simulating gastric (pH 1.2) and intestinal (pH 7.4) conditions. The results demonstrated significantly higher swelling ratios and drug release rates at pH 7.4, indicating pH-responsive characteristics of the formulation, favoring enhanced drug release in the intestinal conditions. Increasing the concentrations of hyaluronic acid and acrylic acid led to enhanced porosity, improved swelling behavior, increased drug loading capacity, faster release rates, and a higher gel fraction, while simultaneously reducing the sol fraction. These observations suggested that the developed pH-sensitive hydrogel holds considerable potential as an effective carrier for pH-responsive, site-specific drug delivery systems. This study highlights the significant advancements in the design of hydrogels with tailored properties for controlled drug release, offering new opportunities for precision medicine.
Long-term, flexible therapy strategies are needed for chronic diseases like cardiovascular ailments, diabetes, and chronic kidney disease and they have to deal with patient heterogeneity, changing physiological states and privacy constraints. This research suggests a framework for privacy-preserving and personalized artificial intelligence that combines Federated Learning (FL), a Res-HyperTransformerNet deep prediction model, Personalized Multi-Agent Reinforcement Learning (PMARL) and Explainable Artificial Intelligence (XAI) for adaptive chronic disease management. The framework is structured with two main aims: (i) to create an accurate and privacy-aware predictive model for chronic disease risk using diverse data sources, and (ii) to permit adaptive, individual therapy optimization through multi-agent reinforcement learning. Federated learning is utilized to conduct the training of Res-HyperTransformerNet over distributed Internet of Medical Things (IoMT) nodes without the requirement of transferring raw patient data. The embeddings that are created from patient data are then passed on to a PMARL module, where several agents optimize therapy dimensions like medications, diet, physical activity, and mental health interventions independently. To make the clinical support more understandable, the SHAP-based explainability method is used for both predictive and decision-making parts. The framework is tested using two public datasets—the CDC Chronic Disease dataset and the UCI Chronic Kidney Disease Risk Factor dataset. The performance is measured by employing classification metrics (accuracy, precision, recall, F1-score, MCC) as well as reinforcement learning metrics (reward score, convergence steps, episode return) and federated system metrics (communication overhead, convergence rounds, and training time). The experiments indicate that the proposed framework demonstrated improved performance in terms of predictive accuracy and policy convergence speed compared to the baseline deep learning and reinforcement learning models, and at the same time it is more cost-effective when it comes to communication in a federated setting. This means that the proposed method suggests the potential of being a reproducible and open AI framework for adaptive chronic disease therapy management. The combination of ResNet and Transformer blocks, i.e., Federated Res-HyperTransformerNet, achieved strong performance in both datasets, namely CDC Chronic Disease (Dataset 1) and UCI CKD Risk Factor (Dataset 2). The obtained accuracy for Dataset 1 was 98.61% and for Dataset 2, it was 97.75%, under the conducted experimental settings.
Journal of Reliable and Secure Computing · مجلد 2 (1) · 1-26
The rapid proliferation of smart home IoT devices has introduced unprecedented cybersecurity vulnerabilities, necessitating scalable and privacy-preserving intrusion detection systems (IDS). Federated Learning (FL) offers a promising decentralized approach by training models locally without sharing raw data, but it remains susceptible to poisoning attacks and relies on a vulnerable central aggregator. This paper presents a novel blockchain-enhanced FL framework tailored for smart home IDS, integrating multiple consensus mechanisms—Proof-of-Stake (PoS), Practical Byzantine Fault Tolerance (PBFT), and Proof-of-Authority (PoA)—for the first time in this context. Our approach uniquely combines differential privacy (DP) and secure aggregation (SA) within a blockchain-managed workflow to mitigate gradient inversion and membership inference attacks while ensuring tamper-resistant, decentralized trust. Experimental evaluation using the N-BaIoT dataset demonstrates that the proposed system achieves up to 88.3% detection accuracy with manageable latency (~200 ms/round) and formal privacy guarantees ($\varepsilon$=1.0 DP). The framework introduces 52.8% system overhead compared to vanilla FL—a reasonable trade-off for enhanced security and privacy. This work establishes a robust, transparent, and scalable security infrastructure for smart homes, effectively addressing the limitations of both centralized and conventional FL-based IDS.
required higher concentrations (84.33% at 75% MBC). These results demonstrated that marine bacterial metabolites produce biocompatible Se-Cu BMNPs with potent antioxidant, anti-inflammatory, antimicrobial, and antibiofilm properties suitable for biomedical applications.
The Eucalyptus globulus essential oil (EGEO) is widely recognized for its pharmacological relevance; however, comprehensive evaluation of its phytochemical composition and bioactivities remains limited. In this study, EGEO was extracted from fresh leaves via hydro-distillation and characterized using GC-MS, LCMS, FTIR, and UV-Visible spectroscopy. Qualitative screening confirmed the presence of key secondary metabolites, including triterpenoids, flavonoids, phenols, steroids. Quantitative analysis revealed high levels of total phenolics (65.12 ± 0.01 mg GAE/g) and flavonoids (57.75 ± 0.01 mg QE/g). The oil exhibited concentration-dependent antioxidant activity in the DPPH assay with an IC₅₀ value of 604.01 µl/mL, indicating potent radical-scavenging ability. Anti-inflammatory assessment through protein denaturation and human red blood cell (HRBC) membrane stabilization assays demonstrated moderate inhibitory and cytoprotective effects comparable to standard drugs. EGEO also showed strong antibacterial efficacy against Tannerella forsythia, Prevotella intermedia and Aggregatibacter with inhibition zones of 19-25 mm while showed notable antibiofilm activity against T. forsythia. Cytotoxic evaluation indicated selective action, showing minimal toxicity toward normal L929 fibroblasts and moderate inhibition of B16F10 melanoma cells. Overall, these findings suggest that Eucalyptus globulus essential oil is a rich source of bioactive phytoconstituents with potential therapeutic applications as a natural antioxidant, anti-inflammatory, antibacterial, antibiofilm, and anticancer agent.
Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors. In this study, a series of twenty-one indole-based derivatives (PSH1 - PSH21) , collectively designated as PSH , was synthesised and evaluated for inhibitory activity against MAO isoforms. Most synthesised compounds showed higher inhibitory activity toward MAO-B than MAO-A, indicating selectivity for MAO-B. Among the PSH derivatives, PSH18 exhibited the most potent MAO-B inhibitory activity (IC 50 = 0.95 ± 0.02 µM), followed by PSH6 ( IC 50 = 1.79 ± 0.40 µM) and PSH2 (IC 50 = 1.96 ± 0.08 µM). Compound PSH18 showed the highest selectivity index value of 42.11, followed by PSH6 (22.35) and PSH2 (20.41). Additionally, PSH18 was confirmed to be a competitive and reversible inhibitor of MAO-B with an inhibition constant value of 0.89 ± 0.035 µM. Notably, PSH18 exhibited good permeability across the blood–brain barrier in parallel artificial membrane permeability assay experiments, along with acceptable absorption, distribution, metabolism, excretion, and toxicity parameters predicted through in silico modelling, suggesting its potential as a central nervous system-targeted molecule. Molecular docking and a 200 ns molecular dynamics simulation demonstrated stable binding of the ligand to the MAO-B active-site pocket, driven by hydrophobic and π–π stacking interactions with key amino acid residues lining the aromatic cage. Moreover, the calculated binding energy indicated strong ligand–protein interactions. Overall, these results indicate that the PSH scaffold could serve as a promising lead structure for the development of potent and selective MAO-B inhibitors. These compounds may have therapeutic potential for the treatment of neurodegenerative diseases.
monoamine oxidase B inhibitorsParkinson's diseaseblood-brain barrier permeabilityADME prediction
The increasing complexity and sophistication of cyber threats have heightened the need for robust security mechanisms throughout the Software Development Lifecycle (SDLC). Traditional security methods have proven insufficient in addressing evolving risks, prompting the exploration of advanced technologies such as Artificial Intelligence (AI). However, integrating AI into SDLC raises challenges related to human-AI collaboration, trust, and alignment. This paper aims to explore the synergistic collaboration between Human Agentic and AI agents to enhance the security of SDLC. By integrating human expertise with AI capabilities, the study investigates how this collaboration can address existing security gaps and improve threat detection, vulnerability management, and secure code development. A qualitative approach is employed, reviewing existing literature on Human-Agentic AI frameworks, AI-driven security models, and their application in SDLC security. We also propose a conceptual framework for Human Agentic-AI collaboration in SDLC security, encompassing AI’s role in automated threat detection, vulnerability scanning, and model optimization, alongside human agents’ roles in decision-making, risk evaluation, and response validation. The proposed framework demonstrates that combining human intuition with AI’s computational power significantly enhances the security posture of SDLC processes. AI’s ability to quickly process and analyze large datasets complements human agents’ contextual understanding, leading to more effective identification of vulnerabilities and proactive security measures. The collaboration results in improved threat mitigation strategies, faster response times, and more reliable secure code deployment. The integration of Human Agentic-AI collaboration offers promising potential in enhancing SDLC security. The synergistic approach bridges the limitations of traditional methods and AI systems, offering a more dynamic and adaptable security solution. Future research should focus on optimizing human-AI interfaces and addressing trust and transparency challenges to further strengthen SDLC security.
International Journal of Polymeric Materials · مجلد 75 (8) · 835-858
Folate-conjugated chitosan nanoparticles represent a promising advancement in targeted drug delivery, offering enhanced specificity, biocompatibility, and controlled release profiles. Chitosan, a versatile biopolymer, provides a stable platform for nanoparticle synthesis, while folate conjugation enables selective targeting of folate receptors, which are overexpressed in various cancers and inflammatory diseases. This review explores the structural and functional properties of chitosan, mechanisms of folate receptor-mediated endocytosis, and innovative strategies for nanoparticle synthesis and functionalization. The review entails key formulation techniques, including nanoprecipitation, ionic gelation, and spray drying, alongside characterization methods essential for optimizing therapeutic efficacy. The biomedical applications of Folate-conjugated chitosan nanoparticles are highlighted in cancer therapy, gene delivery, and anti-inflammatory treatments, with an emphasis on emerging trends such as CRISPR-based targeting and dual-ligand strategies. This review critically examines the existing challenges and explores future directions, highlighting the promising role of folate-conjugated chitosan nanoparticles in the evolution of precision medicine.
targeted drug deliveryfolate receptorreceptor-mediated endocytosisnanoprecipitation
Background and objective: Hyperemesis gravidarum (HG) is a condition that develops early in pregnancy, before 16 weeks of gestation, and is characterized by severe nausea and/or vomiting, inability to tolerate food and/or beverages, and substantial impairment of daily activities. Hyperemesis gravidarum can have obvious maternal and fetal consequences. This study aimed to assess the prevalence of HG, investigate its associated electrolyte and hematologic disturbances, and identify risk factors among pregnant women in Aljouf, Saudi Arabia. Methods: A retrospective observational case-control study was conducted using 200 medical records selected from a total of 9,090 records of pregnant women at the Maternity and Children Hospital in Aljouf, covering the period from November 2020 to November 2023. Results: The prevalence of hyperemesis gravidarum was 1.1% among the studied pregnant women. Patients diagnosed with hyperemesis gravidarum showed significantly lower body weight and BMI than controls. Nearly 48% of HG cases occurred in women aged 30-39 years, while 52% were in the first trimester. Furthermore, 36% of the affected women were primigravida, and 11% were pregnant with twins. Hypotension was observed in 35% of HG cases. Hyponatremia occurred in 29% of patients, hypokalemia in 21%, and hypochloremia in 24%. Hematological disturbances included increased Hb levels in 11% of cases, increased hematocrit in 12%, leukocytosis in 19%, and neutrophilia in 17% of the patients. Conclusion: Hypotension, electrolyte imbalance, and hematological disturbances are the primary consequences of HG. First-trimester pregnancy and low gestational age are the most important risk factors for HG. Strategies by healthcare centers and further research are needed to enhance the treatment, management, and prevention methods of HG.
Toxicology Mechanisms and Methods · مجلد 36 (3) · 412-431
Methotrexate (METX) is a widely used chemotherapeutic and immunosuppressive agent, frequently employed as a first-line treatment for various malignancies and autoimmune disorders. Despite its clinical efficacy, METX is known to induce cardiotoxicity primarily through mechanisms involving oxidative stress, inflammation, and apoptosis. Apigenin (API), a natural dietary flavonoid, exhibits potent antioxidant and anti-inflammatory properties. The current study evaluated the protective effects of API against METX-induced cardiotoxicity in mice, focusing on the modulation of transforming growth factor-β (TGF-β)/(SMAD2) signaling. Molecular docking was done to investigate the possible inhibition of TGF-β by API and bioinformatic tools were utilized to investigate the correlation between the target proteins. Male Swiss albino mice were randomly distributed to four groups: Group I: a saline group, Group II: a METX control group (20 mg/kg, per week), Group III: METX + API (40 mg/kg, per day) and Group IV: METX + API (80 mg/kg, per day, via oral gavage); the study continued for three weeks. Our findings suggest that API administration significantly mitigated METX cardiotoxicity and serum CK-MB, likely through attenuation of the inflammatory cytokines (NF-κB, IL-1β, TNF-α, and IL-6) and suppression of cardiac TGF-β/SMAD2 signaling. The congruence between bioinformatics and experimental validation findings strongly highlighted API as a promising therapeutic candidate for alleviating METX cardiotoxicity. While the current data reveals key underlying molecular mechanisms for API′s cardioprotective effect, further comprehensive studies across diverse cardiotoxicity models are essential to fully elucidate cardioprotective effect of API.
International Journal of Analytical Chemistry · مجلد 2026 (1) · 4376722-4376722
Dasatinib, a therapy for chronic myeloid leukemia, suffers from poor bioavailability. Self‐microemulsifying drug delivery systems (SMEDDSs) are used to improve its dissolution. This study aimed to develop and validate a novel reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method for quantifying dasatinib in SMEDDS formulations. The RP‐HPLC method utilized a mobile phase of methanol and 0.1% trifluoroacetic acid (55:45, v/v) and identified a peak wavelength for dasatinib at 324 nm. SMEDDS formulations comprised Capryol 90, Transcutol HP, and Tween 40. The method was validated according to ICH guidelines, demonstrating excellent linearity ( R 2 = 0.9993), accuracy (recovery between 98% and 101%), and precision (relative standard deviation of 0.73%). It also showed stability and reliability with limits of detection and quantification of 0.17 and 0.50 µg/mL, respectively. This RP‐HPLC method meets all validation criteria and provides a robust, cost‐effective tool for analyzing dasatinib in SMEDDS formulations.
dasatinibself-microemulsifying drug delivery systemRP-HPLC method developmentmethod validation
The Lancet Child & Adolescent Health · مجلد 10 (10) · 731-754
BACKGROUND: The Asia Pacific region is home to more than half of the world's 1·93 billion adolescents (aged 10-24 years). Addressing adolescent health in this region is of global importance, but to date a systematic analysis of key contributors to disease in adolescents has not been done, which is a barrier to responsive action. This systematic analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 aims to provide a comprehensive assessment of adolescent health across the Asia Pacific region, at both the subregional and national levels, encompassing burden of disease, mortality, and prevalence of adolescent risk factors. METHODS: As part of GBD 2023, we obtained estimates for cause-specific mortality, disability-adjusted life-years (DALYs), and risk factor prevalence by sex for adolescents aged 10-24 years and 5-year age groups (10-14 years, 15-19 years, and 20-24 years) across 44 countries and territories (hereafter referred to collectively as Asia Pacific), grouped by seven UN subregions, from 2000 to 2023. We extracted GBD 2023 population counts and estimates of number and rate (per 100 000 population) for mortality and disease burden (DALYs). Risk prevalence estimates were obtained directly from the Institute for Health Metrics and Evaluation, and binge drinking estimates were sourced from WHO. Estimates are reported with 95% uncertainty intervals (UIs) where possible. UIs were estimated by running 250 draws of the posterior distribution, ordering the draws, and selecting the 2·5th and 97·5th percentiles for each metric. FINDINGS: In 2023, in adolescents across Asia Pacific, there were 637 496 deaths and a total disease burden of 115·8 million DALYs, representing 34·1% of global adolescent deaths and 40·6% of the global adolescent burden of disease. Non-communicable diseases (NCDs; particularly mental disorders) were the leading causes of disease burden and mortality (64·8% of DALYs and 43·9% of deaths). Unintentional and transport injuries were also leading causes of death (14·7% of deaths due to transport injury and 13·3% of deaths due to unintentional injury) and leading causes of disease burden particularly among males in south-eastern Asia. In Melanesia, Micronesia, and some parts of south-eastern Asia (Cambodia, Indonesia, Laos, the Philippines, and Timor-Leste), respiratory infections and tuberculosis remained important contributors. Southern Asia had the largest reduction (1·5% per year) in all-cause DALYs over the study period, and Australia and New Zealand (0·2% per year) had the smallest, with females in Australia and New Zealand showing a slight increase contrary to regional trends. Eastern Asia had the largest reduction (2·8% per year) in all-cause mortality rate and Melanesia (0·8% per year) the smallest. Risk factors generally had between-subregion and within-subregion variation; however, some regional trends stood out, with overweight and obesity increasing in all countries across the region, and binge drinking increasing in more countries than not. In 2023, prevalence of smoking in males exceeded that in females in every country, from 40% difference in Timor-Leste to less than 1% difference in Australia. Anaemia prevalence is decreasing in all countries, but female prevalence was higher and reducing at a slower rate than in males. Bullying prevalence was slightly higher in Polynesia, Micronesia, and Melanesia combined, Australia and New Zealand, and eastern Asia compared with southern and south-eastern Asian subregions. INTERPRETATION: Several patterns were consistent across the region: the dominance of mental disorders and NCDs, the universal rise in overweight and obesity (particularly high in Oceanic countries but increasing rapidly in south and south-eastern Asia), and persistent sex-specific challenges across subregions: unintentional injuries and smoking in males, and anaemia in females. Actions to tackle shared risk factors (while accounting for context-specific local health profiles, workforce deficits, cultural factors, and health system capacity) should not be forgone due to local variation. Future research could focus on subnational variation, intersecting inequalities, and multi-sectoral interventions targeting shared risk factors. Priority actions should include regional investment in adolescent mental health services and obesity prevention, targeted injury reduction strategies for high-risk populations, and sex-specific approaches to smoking cessation and anaemia reduction, delivered through local health systems with the capacity and cultural responsiveness to meet local needs. FUNDING: Gates Foundation and Australian Government.
adolescent healthdisease burdenadolescent mortalitydisability-adjusted life years
Background: Chronic nonspecific low back pain (CNSLBP) is a musculoskeletal condition characterized by persistent discomfort, weak trunk muscles, exhaustion, and disability. Objectives: The purpose of this study is to compare the effects of high-intensity laser acupuncture (HILA) and low-intensity laser acupuncture (LILA), combined with exercise, on strength of trunk extensors, fatigue, level of pain, range of motion (ROM) of lumbar flexion, and disability in patients with CNSLBP. Materials and methods: 60 participants with CNSLBP were divided into three groups in this randomized, double-blind, sham-controlled trial: the high-intensity laser (HILA) group, who received HILA over 15 acupuncture points along with exercises; the low-intensity laser (LILA) group, who received LILA over the same points plus exercises; and the sham group, who received sham laser in addition to exercises. The interventions were received three times/week for four consecutive weeks. The strength of trunk extensors, fatigue, pain, lumbar flexion ROM, and disability were measured at baseline, after 4 weeks, and at a 1-month follow-up. The assessment tools used included isokinetic dynamometry, the visual analogue scale (VAS), the modified Schober test (MST), and the Oswestry Disability Index (ODI). Results: < 0.05). However, fatigue and disability did not differ between the two active laser groups. All groups showed minor changes between the post-treatment and follow-up periods. Conclusion: Patients with CNSLBP may have a short-term benefit from HILA and LILA combined with exercise rather than from exercise alone in terms of trunk extensor strength and fatigue, pain, lumbar flexion ROM, and disability. However, both laser treatments showed comparable effects on fatigue and disability; HILA appears to be more effective than LILA in improving trunk extensor strength and relieving pain. To define the ideal treatment parameters and to evaluate long-term effects, further research is required. Clinical Trial Registration: https://clinicaltrials.gov/, identifier [NCT06280846].
chronic non-specific low back painlaser acupunctureexercise therapytrunk extensor strength